A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study

作者：Rocereto Thomas F^*; Brady William E; Shahin Mark S; Hoffman James S; Small Laurie; Rotmensch Jacob; Mannel Robert S

来源：Gynecologic Oncology, 2010, 116(3): 332-334.

DOI：10.1016/j.ygyno.2009.10.071

• Mifepristone
• GOG
• Epithelial ovarian cancer
• Fallopian cancer
• Primary peritoneal cancer

Objective. To evaluate the effectiveness and toxicity of mifepristone in patients with ovarian, peritoneal and fallopian tube cancers.
Methods. Patients with confirmed epithelial ovarian, peritoneal and fallopian tube cancers which were persistent or recurred in less then I year after primary chemotherapy were entered into this study. Patients were given mifepristone 200 mg by mouth daily for a 28 day cycle. The medication was stopped for unacceptable toxicity or tumor progression.
Results. Twenty-four patients were entered into the study. Twenty-two patients were evaluable for response. Only one patient had a partial response for a response rate of only 4.5% (90% confidence interval: 0.2%, 19.8%).
Conclusion. Mifepristone has not proven to be an effective agent in the treatment of patients with recurrent or persistent ovarian, peritoneal and fallopian tube cancers.

• 出版日期2010-3